Matrix metalloproteinase-9 expression is a marker of aggressive esophageal carcinoma: a meta-analysis
Keywords:
Matrix metalloproteinase-9, Esophageal cancer, Biomarker, Meta-analysisAbstract
Background: Matrix metalloproteinase-9 (MMP-9) is the proteolytic enzyme degrades type IV collagen in basement membrane causing tumor invasion and metastasis. The purpose of the study is to evaluate whether MMP-9 expression is associated with aggressiveness of esophageal carcinoma.
Method: A search was performed on Pubmed, EMBASE, Google scholar and the Cochrane database until March 2014. A meta-analysis was conducted to investigate the association between MMP-9 expression and clinicopathological characteristics of esophageal cancer.
Result: The final analysis included 673 esophageal cancer patients from 9 studies. MMP-9 expression was determined on biopsy or surgical specimens by IHC. The pooled data demonstrated that positive MMP-9 expression was significantly associated with poorer tumor differentiation (OR = 1.71, 95% CI: 1.13, 2.58; p = 0.01), lymph node metastasis (OR = 1.80, 95% CI: 1.20, 2.71; p = 0.005) and vascular invasion (OR = 2.55, 95% CI: 1.54, 4.21; p = 0.003). However, there were no significant associations between MMP-9 expressions and advanced tumor staging, depth of tumor invasion and lymphatic invasion.
Conclusion: The expression of MMP-9 is associated with poorer tumor differentiation, lymph node metastasis and vascular invasion. MMP-9 expression could be a valuable marker for aggressiveness of esophageal cancer.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.